Defosbarasertib, IMFINZI 50 mg/mL concentrate for solution for infusion.
D6132C00001
Phase 2 small_molecule active
Quick answer
Defosbarasertib, IMFINZI 50 mg/mL concentrate for solution for infusion. for First-line patients with extensive disease small-cell lung cancer (SCLC) is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- First-line patients with extensive disease small-cell lung cancer (SCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active